ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS
Phase of Trial: Phase III
Latest Information Update: 15 Mar 2019
Price : $35 *
At a glance
- Drugs Crisaborole (Primary) ; Tacrolimus
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Acronyms ASPIRE
- 11 Mar 2019 Status changed from not yet recruiting to recruiting.
- 22 Jan 2019 Planned End Date changed from 31 Aug 2020 to 30 Sep 2020.
- 22 Jan 2019 Planned primary completion date changed from 30 Apr 2020 to 30 Jun 2020.